Related Experiment Videos
Controlled trial on three beta-blockers: antihypertensive efficacy and effect on the hypertensive heart disease
Insights
This study shows that three beta-blockers significantly reduced blood pressure and heart rate in hypertensive patients. Nadolol demonstrated the greatest reduction in blood pressure and hypertrophy.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension is a major risk factor for cardiovascular disease.
- Beta-blockers are commonly prescribed for hypertension management.
- Assessing the comparative efficacy of different beta-blockers is crucial.
Purpose of the Study:
- To compare the efficacy of three different beta-blockers in treating hypertension.
- To evaluate the effects of atenolol, oxprenolol, and nadolol on blood pressure, heart rate, and left ventricular function.
Main Methods:
- A six-month study involving 66 hypertensive patients.
- Patients were treated with atenolol (100 mg/day), oxprenolol (80 mg twice daily), or nadolol (80 mg/day).
- Measurements included blood pressure, heart rate, pre-ejection period/left ventricular ejection time ratio, and the Romhilt-Estes index for left ventricular hypertrophy.
Main Results:
- All three beta-blockers significantly reduced blood pressure and heart rate.
- Nadolol showed the most significant reduction in blood pressure and heart rate.
- Atenolol and nadolol improved the pre-ejection period/left ventricular ejection time ratio, indicating better left ventricular performance.
- All drugs reduced left ventricular hypertrophy, with nadolol showing the most pronounced effect.
Conclusions:
- Atenolol, oxprenolol, and nadolol are effective in managing hypertension and reducing left ventricular hypertrophy.
- Nadolol appears to be the most effective among the three studied beta-blockers for blood pressure reduction and improving cardiac function.
Abstract:
Treatment of 66 hypertensive patients with three different beta-blockers (atenolol 100 mg once a day; oxprenolol 80 mg twice a day; nadolol 80 mg once a day) for six months resulted in a significant reduction in blood pressure and heart rate, the maximum with nadolol, a significant amelioration in pre-ejection period/left ventricular ejection time ratio expressing the haemodynamic performance of the left ventricle with atenolol and nadolol, and a significant reduction left ventricular hypertrophy as expressed by the Romhilt-Estes index with all three drugs, but especially with nadolol.